Latest Regulatory Milestones News

Anteris Technologies has secured its first European regulatory clearance to commence the global PARADIGM Trial for its DurAVR Transcatheter Heart Valve, marking a significant step toward worldwide commercialization.

Moho Resources has reported new high-grade gold assays up to 6.98g/t at its Bush Chook Project in Western Australia, extending a mineralised trend to 300 metres and setting the stage for a maiden drill program later this year or early next.

VHM Limited has secured a significant offtake framework with Mitsui and a US$200 million financing interest from the US Export-Import Bank for its Goschen Rare Earths and Mineral Sands Project, alongside key environmental approvals. These milestones set the stage for a Final Investment Decision in the first half of 2026.

Biotron Limited is set to acquire Sedarex Limited, gaining global patents for SedRx, a next-generation general anaesthetic, supported by a $2.5 million capital raising to fund regulatory and development milestones.

Compumedics has secured a $2.15 million placement to fast-track commercialisation of its Somfit D device following early FDA approval, positioning the company for significant growth in the US home sleep testing market.

Cobre Limited has secured Environmental Impact Assessment approval for its In-Situ Copper Recovery pilot plant in Botswana, marking a pivotal step towards project development.

Proteomics International has expanded its partnership with the University of Melbourne and Royal Women’s Hospital to further validate and develop its PromarkerEndo blood test, aiming to revolutionize endometriosis diagnosis.

Infomedia Limited has received crucial regulatory clearance from the German Federal Ministry for Economic Affairs and Energy for its proposed acquisition by McQueen BidCo, advancing the scheme of arrangement. The company’s board continues to recommend shareholder approval amid remaining conditions.

PYC Therapeutics has reported encouraging pre-clinical results for its RNA therapy candidate PYC-002 targeting Phelan-McDermid Syndrome, supporting plans to enter human trials in 2026. The data demonstrate safety, brain distribution, and gene expression restoration in key disease regions.

Immutep Limited has confirmed 30 mg as the optimal biological dose for its immunotherapy efti, following FDA approval of Project Optimus requirements. This milestone paves the way for the US launch of its pivotal Phase III lung cancer trial.

Centaurus Metals has secured the final mining lease for its Jaguar Nickel Project in Brazil, clearing a major regulatory hurdle and moving closer to a Final Investment Decision and project development.

Artrya Limited has successfully navigated a key FDA Q-Submission meeting, receiving clear guidance on the regulatory pathway for its Salix Coronary Flow module, with a 510(k) submission planned by year-end.